TNFα modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer

[1]  S. Chiang,et al.  Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation , 2023, Cancer Immunology, Immunotherapy.

[2]  S. Chiang,et al.  Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade , 2022, Cell Death & Disease.

[3]  M. Elvers,et al.  Pannexin-1 Activation by Phosphorylation Is Crucial for Platelet Aggregation and Thrombus Formation , 2022, International journal of molecular sciences.

[4]  S. Chiang,et al.  Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy , 2021, Cancers.

[5]  L. Galluzzi,et al.  Detection of immunogenic cell death and its relevance for cancer therapy , 2020, Cell Death & Disease.

[6]  Jun Lu,et al.  Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy , 2020, Cellular Oncology.

[7]  V. Roulstone,et al.  RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma , 2020, EMBO molecular medicine.

[8]  J. Jeyaraman,et al.  Conformational insights into the inhibitory mechanism of phyto-compounds against Src kinase family members implicated in psoriasis , 2020, Journal of biomolecular structure & dynamics.

[9]  S. Chiang,et al.  Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer , 2020, Cancers.

[10]  Kaiwen W. Chen,et al.  Pannexin‐1 promotes NLRP3 activation during apoptosis but is dispensable for canonical or noncanonical inflammasome activation , 2020, European journal of immunology.

[11]  Ashley M. Miller,et al.  Endothelial Pannexin 1 Channels Control Inflammation by Regulating Intracellular Calcium , 2019, The Journal of Immunology.

[12]  N. Bidère,et al.  Pannexin-1 limits the production of proinflammatory cytokines during necroptosis. , 2019, EMBO reports.

[13]  N. Meyer,et al.  The TNF Paradox in Cancer Progression and Immunotherapy , 2019, Front. Immunol..

[14]  T. Schumacher,et al.  Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold , 2019, Cell.

[15]  A. Degterev,et al.  Targeting RIPK1 for the treatment of human diseases , 2019, Proceedings of the National Academy of Sciences.

[16]  Kaiwen W. Chen,et al.  Extrinsic and intrinsic apoptosis activate pannexin‐1 to drive NLRP3 inflammasome assembly , 2019, The EMBO journal.

[17]  F. Di Virgilio,et al.  The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment , 2019, Oncogene.

[18]  G. Adema,et al.  Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? , 2018, Front. Immunol..

[19]  K. Brown,et al.  Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.

[20]  G. Beldi,et al.  Mechanisms of ATP Release by Inflammatory Cells , 2018, International journal of molecular sciences.

[21]  S. Chiang,et al.  Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy , 2018, Cancer Immunology, Immunotherapy.

[22]  J. Sheu,et al.  RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer , 2018, BioMedicine.

[23]  J. Sáez,et al.  ATP promotes the fast migration of dendritic cells through the activity of pannexin 1 channels and P2X7 receptors , 2017, Science Signaling.

[24]  C. Mitchell,et al.  The P2X7 Receptor Primes IL-1β and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain , 2017, Front. Cell. Neurosci..

[25]  Elena De Marchi,et al.  P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses. , 2017, Current medicinal chemistry.

[26]  Matthew L. Albert,et al.  Dying cells actively regulate adaptive immune responses , 2017, Nature Reviews Immunology.

[27]  Wei Li,et al.  TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells , 2017, Cancer Cell International.

[28]  M. Bertrand,et al.  Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity. , 2016, Cell reports.

[29]  D. Green,et al.  RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells , 2015, Science.

[30]  K. Stokes,et al.  Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation , 2015, Nature Communications.

[31]  S. Cullen,et al.  Diverse Activators of the NLRP3 Inflammasome Promote IL-1β Secretion by Triggering Necrosis. , 2015, Cell reports.

[32]  W. Schulz-Schaeffer,et al.  Depletion of Cutaneous Macrophages and Dendritic Cells Promotes Growth of Basal Cell Carcinoma in Mice , 2014, PloS one.

[33]  S. Demaria,et al.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death , 2014, Oncoimmunology.

[34]  H. Hoekstra,et al.  Isolated limb perfusion for in‐transit melanoma metastases: Melphalan or TNF‐melphalan perfusion? , 2014, Journal of surgical oncology.

[35]  D. Yoon,et al.  IL‐32γ enhances TNF‐α‐induced cell death in colon cancer , 2014, Molecular carcinogenesis.

[36]  L. Zitvogel,et al.  Molecular mechanisms of ATP secretion during immunogenic cell death , 2013, Cell Death and Differentiation.

[37]  L. Diaz,et al.  Systemic use of tumor necrosis factor alpha as an anticancer agent , 2011, Oncotarget.

[38]  G. Dubyak,et al.  Pannexin-1 Is Required for ATP Release during Apoptosis but Not for Inflammasome Activation , 2011, The Journal of Immunology.

[39]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[40]  D. Diaconu,et al.  Depletion of antigen‐presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC‐Tie2 mice , 2011, The British journal of dermatology.

[41]  Michael R. Elliott,et al.  Pannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis , 2010, Nature.

[42]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[43]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[44]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[45]  W. Britton,et al.  A Loss-of-Function Polymorphism in the Human P2X7 Receptor Abolishes ATP-Mediated Killing of Mycobacteria 1 , 2003, The Journal of Immunology.

[46]  W. Alvord,et al.  TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-γ Double Knockout Effector T Cells 1 , 2003, The Journal of Immunology.

[47]  M. Maes,et al.  Pannexin1 as mediator of inflammation and cell death. , 2017, Biochimica et biophysica acta. Molecular cell research.